Nagaraj Karthik, Vandenbussche Nicolas, Goadsby Peter J
Department of Neurology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.
Department of Neurology, Ghent University Hospital, Ghent, Belgium.
Neurol India. 2021 Mar-Apr;69(Supplement):S59-S66. doi: 10.4103/0028-3886.315997.
Medications targeting the calcitonin gene-related peptide (CGRP) pathway are exciting and novel therapeutic options in the treatment of migraine.
In this article, we have reviewed the role of these CGRP monoclonal antibodies in patients with episodic migraine.
We did an extensive literature search for all phase 2 and 3 studies involving CGRP monoclonal antibodies in episodic migraine.
Erenumab, fremanezumab, galcanezumab, and eptinezumab have all undergone phase 3 trials and have been found to be effective for episodic and chronic migraine. They have the advantage of being targeted therapies for migraine with very favorable adverse effect profiles comparable to placebo. Importantly, they are effective in subgroups of patients who have failed previous preventive therapies.
Increasing use of these medications will certainly revolutionize the treatment and outlook for patients with migraine all over the world.
靶向降钙素基因相关肽（CGRP）通路的药物是偏头痛治疗中令人兴奋的新型治疗选择。
在本文中，我们综述了这些CGRP单克隆抗体在发作性偏头痛患者中的作用。
我们对所有涉及CGRP单克隆抗体治疗发作性偏头痛的2期和3期研究进行了广泛的文献检索。
erenumab、fremanezumab、galcanezumab和eptinezumab均已完成3期试验，并被发现对发作性和慢性偏头痛有效。它们具有作为偏头痛靶向治疗的优势，不良反应谱与安慰剂相当，非常有利。重要的是，它们对先前预防性治疗失败的患者亚组有效。
这些药物的使用增加必将彻底改变全球偏头痛患者的治疗和前景。
